
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.
This trial is looking at durvalumab and domvanalimab for non small cell lung cancer that has grown into surrounding tissues.
It is for people with non small cell lung cancer that:
Chemoradiotherapy is a usual treatment for non small cell lung cancer. It is a combination of chemotherapy and radiotherapy. You might have durvalumab after this to strengthen the effect of the chemoradiotherapy.
Durvalumab is an immunotherapy. It works by stimulating the to find and kill cancer cells. This can slow down or stop the growth of the cancer.
Domvanalimab is a new drug and is another type of immunotherapy. It targets cancer cells in a slightly different way to durvalumab.
We know from early research that adding domvanalimab to durvalumab might work better than durvalumab on its own. So doctors are running this trial to find out more.
In this trial some people have durvalumab and domvanalimab. And some have durvalumab and a dummy drug ().
The main aims of the trial are to find out:
The following bullet points are a summary of the entry conditions for this trial. Talk to your doctor or the trial team if you are unsure about any of these. They will be able to advise you.
Who can take part
You may be able to join this trial if all of the following apply. You:
Who can’t take part
Cancer related
You cannot join this trial if any of these apply. You:
Medical conditions
You cannot join this trial if any of these apply. You:
Other
You cannot join this trial if any of these apply. You:
This is a phase 3 trial. The trial team need about 860 people to have the treatment in this trial. This includes 28 people from the UK.
It is a randomised trial. You are put into a group by a computer. Neither you nor your doctor will be able to decide which group you are in. Nor will either of you know which group you are in.
There are 2 treatment groups. You have 1 of the following:
You have durvalumab, domvanalimab or the dummy drug as a drip into a vein. You have treatment once a month. You have durvalumab first followed by domvanalimab or the dummy drug.
You have treatment once every 4 weeks for up to 1 year for as long as it is working and the side effects aren’t too bad.
You stop treatment if your cancer gets worse. The trial team will talk to you about other treatment options.
Blood and tissue samples for research
The researchers ask you to give an extra tissue sample. They also ask to take some extra blood samples. Where possible, you have these at the same time as your routine blood tests.
They plan to use the samples to:
You need to agree to give most of the samples to take part in the trial. There are a few samples you can say no to. The team can let you know more about this.
Quality of life
The trial team ask you to fill out some questionnaires:
The questionnaires ask about side effects and how you’ve been feeling. This is called a quality of life study.
You see the doctor and have tests before you can take part. These include:
You have your treatment at the hospital on the day care ward. You shouldn’t’ need to stay overnight.
You go to the hospital every 2 weeks in the first month of treatment for a check up and blood tests. After that you have a check up once a month.
You have a CT or MRI scan every:
You have the trial scans until your cancer gets worse. You also have one more scan at least a month later if your cancer does get worse.
When you finish treatment, you see the trial team for a check up once a month for 4 months. The team then contact you every 2 months to see how you are getting on. They will check if you have started another cancer treatment.
The trial team monitor you during treatment and afterwards. Contact your advice line or tell your doctor or nurse if any side effects are bad or not getting better.
Durvalumab and domvanalimab can affect the These side effects could happen during treatment or months after treatment has finished. Rarely, these side effects could be life threatening. Your doctor or nurse can explain what these side effects are, the risk of them happening and what to look out for. |
Domvanalimab is a new drug. Only a few hundred people have had it so there may be some side effects we don’t know about yet.
The most common side effects of domvanalimab include:
We have information about durvalumab and its side effects.
Durvalumab and domvanalimab is a new combination of treatment. So there may be some side effects we don’t know about yet.
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Shobhit Baijal
AstraZeneca
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
Last year in the UK over 60,000 cancer patients enrolled on clinical trials aimed at improving cancer treatments and making them available to all.